Sandbox/intraabdominal: Difference between revisions

Jump to navigation Jump to search
Guillermo Rodriguez Nava (talk | contribs)
No edit summary
Guillermo Rodriguez Nava (talk | contribs)
Line 245: Line 245:
{|
{|
| valign=top |
| valign=top |
<div style="border-radius: 5px 5px 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 45px; line-height: 45px; width: 225px; background: #A1BCDD; text-align: center;">
<div style="border-radius: 5px 5px 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 47px; line-height: 47px; width: 225px; background: #A1BCDD; text-align: center;">
<font color="#FFF">
<font color="#FFF">
'''Multidrug resistant gram-negative bacilli'''
'''Multidrug resistant gram-negative bacilli'''
Line 269: Line 269:
</div>
</div>


<div style="border-radius: 0 0 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 45px; line-height: 45px; width: 225px; background: #A1BCDD; text-align: center;">
<div style="border-radius: 0 0 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 47px; line-height: 47px; width: 225px; background: #A1BCDD; text-align: center;">
<font color="#FFF">
<font color="#FFF">
'''''Pseudomonas aeruginosa''''' '''>20% resistant to ceftazidime'''
'''''Pseudomonas aeruginosa''''' '''>20% resistant to ceftazidime'''
Line 294: Line 294:


| valign=top |
| valign=top |
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table01" style="background: #FFFFFF;"
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table07" style="background: #FFFFFF;"
| valign=top |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center| {{fontcolor|#FFF|Single agent}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center| {{fontcolor|#FFF|Single agent}}
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ertapenem]] 3 months to 12 years 15 mg/kg IV q12h; >13 years 1 g IV q24h'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Carbapenem
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Meropenem]] 1 g IV q8h'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Meropenem]] 60 mg/kg/day IV q8h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Imipenem]]/[[Cilastatin]] 500 g IV q6h or 1 g q8h'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Imipenem]]/[[Cilastatin]] 60-100 mg/kg/day IV q4-6h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doripenem]] 500 g IV q8h'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Cephalosporin-based
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ceftazidime]] 200-300 mg/kg/day IV q12h'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ticarcillin]]-[[Clavulanate]] 200-300 mg/kg/day IV q12h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Cefepime]] 200-300 mg/kg/day IV q12h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Metronidazole]] 500 mg IV q8-12h or 1.5 g q24h'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Penicillin-based
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Piperacillin]]-[[Tazobactam]] 200-300 mg/kg/day IV q6-8h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Piperacillin]]-[[Tazobactam]] 3.375 g q4h or 4.5 g q6h '''''
|-
|-
|}
|}

Revision as of 17:14, 12 June 2014

Initial Empiric Treatment of Extra-biliary Community-acquired Complicated Intra-abdominal Infection

▸ Click on the following categories to expand treatment regimens.

Pediatric patients

  ▸  Single agent

  ▸  Combination

Adults, mild-to-moderate severity

  ▸  Single agent

  ▸  Combination

Adults, high risk or severity

  ▸  Single agent

  ▸  Combination

Single agent
Ertapenem 3 months to 12 years 15 mg/kg IV q12h; >13 years 1 g IV q24h
OR
Meropenem 60 mg/kg/day IV q8h
OR
Imipenem/Cilastatin 60-100 mg/kg/day IV q4-6h
OR
Ticarcillin-Clavulanate 200-300 mg/kg/day IV q12h
OR
Piperacillin-Tazobactam 200-300 mg/kg/day IV q6-8h
Combination
Ceftriaxone 50-70 mg/kg/day IV q12-24h
OR
Cefotaxime 150-200 mg/kg/day IV q6-8h
OR
Cefepime 100 mg/kg/day IV q12h
OR
Ceftazidime 150 mg/kg/day IV q8h
PLUS
Metronidazole 30-40 mg/kg/day IV q8h
OR
Gentamicin 3-7.5 mg/kg/day IV q2-4h
OR
tobramycin 3-7.5 mg/kg/day IV q8-24h
PLUS
Metronidazole 30-40 mg/kg/day IV q8h
OR
Clindamycin 20-40 mg/kg/day IV q6-8h
WITH OR WITHOUT
Ampicillin 200 mg/kg/day IV q8-24h
Single agent
Cefoxitin 2 g IV q6h
OR
Ertapenem 1 g IV q24h
OR
Moxifloxacin 400 mg IV q24h
OR
Tigecycline 100 mg initial dose, then 50 mg IV q12h
OR
Ticarcillin-Clavulanic acid 200 mg/kg/day IV q6h
Combination
Cefazolin 1-2 g IV q8h
OR
Cefuroxime 1.5 g IV q8h
OR
Ceftriaxone 1-2 g IV q12-24h
OR
Cefotaxime 1-2 g IV q6-8h
OR
Ciprofloxacin 400 mg IV q12h
OR
Levofloxacin 750 mg IV q24h
PLUS
Metronidazole 500 mg IV q8-12h or 1.5 g q24h
Single agent
Imipenem-Cilastatin 500 g IV q8h
OR
Meropenem 1 g IV q8h
OR
Doripenem 500 g IV q8h
OR
Piperacillin-Tazobactam 3.375 g IV q6h
For Pseudomonas aeruginosa may be increased to 3.375 g q4h or 4.5 g q6h .
Combination
Cefepime 2 g IV q8-12h
OR
Ceftazidime 2 g IV q8h
OR
Ciprofloxacin 400 g IV q12h
OR
Levofloxacin 750 mg IV q24h
PLUS
Metronidazole 500 mg IV q8-12h or 1.5 g q24h

Empiric Antimicrobial Therapy for Health Care-Associated Complicated Intra-abdominal Infection

▸ Click on the following categories to expand treatment regimens.

Multidrug resistant gram-negative bacilli

  ▸  Regimen

ESBL-Enterobacteriaceae

  ▸  Regimen

Pseudomonas aeruginosa >20% resistant to ceftazidime

  ▸  Regimen

MRSA

  ▸  Regimen

Single agent
Carbapenem
Meropenem 1 g IV q8h
OR
Imipenem/Cilastatin 500 g IV q6h or 1 g q8h
OR
Doripenem 500 g IV q8h
Cephalosporin-based
Ceftazidime 200-300 mg/kg/day IV q12h
OR
Cefepime 200-300 mg/kg/day IV q12h
PLUS
Metronidazole 500 mg IV q8-12h or 1.5 g q24h
Penicillin-based
Piperacillin-Tazobactam 3.375 g q4h or 4.5 g q6h
Combination
Ceftriaxone 50-70 mg/kg/day IV q12-24h
OR
Cefotaxime 150-200 mg/kg/day IV q6-8h
OR
Cefepime 100 mg/kg/day IV q12h
OR
Ceftazidime 150 mg/kg/day IV q8h
PLUS
Metronidazole 30-40 mg/kg/day IV q8h
OR
Gentamicin 3-7.5 mg/kg/day IV q2-4h
OR
tobramycin 3-7.5 mg/kg/day IV q8-24h
PLUS
Metronidazole 30-40 mg/kg/day IV q8h
OR
Clindamycin 20-40 mg/kg/day IV q6-8h
WITH OR WITHOUT
Ampicillin 200 mg/kg/day IV q8-24h
Single agent
Cefoxitin 2 g IV q6h
OR
Ertapenem 1 g IV q24h
OR
Moxifloxacin 400 mg IV q24h
OR
Tigecycline 100 mg initial dose, then 50 mg IV q12h
OR
Ticarcillin-Clavulanic acid 200 mg/kg/day IV q6h
Combination
Cefazolin 1-2 g IV q8h
OR
Cefuroxime 1.5 g IV q8h
OR
Ceftriaxone 1-2 g IV q12-24h
OR
Cefotaxime 1-2 g IV q6-8h
OR
Ciprofloxacin 400 mg IV q12h
OR
Levofloxacin 750 mg IV q24h
PLUS
Metronidazole 500 mg IV q8-12h or 1.5 g q24h
Single agent
Imipenem-Cilastatin 500 g IV q8h
OR
Meropenem 1 g IV q8h
OR
Doripenem 500 g IV q8h
OR
Piperacillin-Tazobactam 3.375 g IV q6h
For Pseudomonas aeruginosa may be increased to 3.375 g q4h or 4.5 g q6h .
Combination
Cefepime 2 g IV q8-12h
OR
Ceftazidime 2 g IV q8h
OR
Ciprofloxacin 400 g IV q12h
OR
Levofloxacin 750 mg IV q24h
PLUS
Metronidazole 500 mg IV q8-12h or 1.5 g q24h